Fernanda Martins Rodrigues’s indexed work centers on germline predisposition in multiple myeloma and the pan-cancer impact of germline variants. Her first-authored 2024 iScience paper (12 citations) characterizes germline predisposition in multiple myeloma, while her 2025 Cell paper (8 citations) uses a precision proteogenomics approach to reveal how inherited variants influence cancer proteomes across tumor types. Earlier work includes a 2017 BMC Genomics study (5 citations) that examined transcriptional variation in muscle tissue linked to alternative NCAPG/LCORL haplotypes in cattle. Rodrigues has also contributed as a middle author to several high-impact consortium efforts, including the 2021 Cell proteogenomic portrait of lung squamous cell carcinoma (392 citations) and the 2023 Cancer Cell pan-cancer proteogenomics study connecting oncogenic drivers to functional states (109 citations). She additionally developed CharGer, a tool for clinical characterization of germline variants, published in Bioinformatics (60 citations). Across these works, her research consistently bridges germline genetics, proteogenomics, and cancer biology to understand how inherited variation shapes disease risk and molecular phenotypes.